Hemoglobin variants and thalassemias are two genetically distinct hemoglobin abnormalities. Thalassemias are characterized by a reduced synthesis of the normal globin chain due to gene deletions or mutations. The most common thalassemias are alpha- and beta-thalassemias. The hemoglobin variants are caused by amino acid substitutions in either globin chain. Globally, more than 1800 hemoglobin variants have been characterized(4,5) but only a few are widely common: Hb S, Hb C, Hb E and Hb D-Punjab.
Hemoglobinopathies can present several clinical symptoms, from benign (mild microcytosis) to the most severe (sickle cell disease, Hb Bart’s hydrops fetalis, …) with multiple organ damage, requiring lifelong transfusions. Diagnosis and follow-up of hemoglobinopathies depend on the presence of abnormal hemoglobin fractions on electrophoresis profiles and the quantification of Hb A2.
For more than 20 years, Sebia has developed a strong expertise in the field of hemoglobin disorders screening and is a recognised partner of choice for all laboratories and scientists involved in hemoglobinopathies.
In addition to hematological RBC parameters, the information on the type and quantification of hemoglobin given by the CE technique provides key information in the screening of hemoglobinopathies such as Thalassemia or Sickle Cell Disease(4,5).
In this report, we evaluated the use of the capillary electrophoresis (CE) migration position in the CAPILLARYS 2 CE instrument.
This article assesses the performances of the different manufacturers and technologies (HPLC and CE) for Hb A2 measurement using both International Reference Reagent for HbA2 (WHO IRR 89/666) and analysis of three whole blood specimens over a range of HbA2, distributed to 56 laboratories located in 14 different countries.
With this short video report, become aware of all the benefits of partnering with Sebia and integrate your capillary electrophoresis into the lab track automation.
The perfect match for screening hemoglobin disorders in newborns
This special Issue related to newborn screening for Sickle Cell disease and other hemoglobinopathies tried to cover the most widely faced challenges in the field of newborn screening for SCD.
Educational Webinar Dr. Cornelia L. Harteveld from Leiden University Medical Center
Educational Webinar with Jason EYRE
IFCC Euromedlab 2021
Sebia booth: #121
Sebia Workshop: EduW22
IFCC Worldlab 2022
Sebia booth: #72
Sebia Workshop: EduW25
IFCC Euromedlab /WorldLab 2023
Sebia booth: #21
Sebia Workshop: EduW15
Evolution makes the difference.
The power of up to 36 capillaries in one automated high volume workcell.
Large menu with high quality results on gel electrophoresis.
The compact and affordable automation of Capillary Electrophoresis.
The high throughput solution for newborn hemoglobin disorders screening.
The high-resolution method for hemoglobin disorders screening.
The perfect match for screening hemoglobin disorders in newborns.
This section contains information intended for wide distribution and may therefore contain product details or information that is not available or valid in your country.
Please contact your local Sebia representative. Information intended for healthcare professionals.
Carefully read the instructions in the reagent package inserts and instrument manuals.